Skip to main content

Advertisement

Table 1 Patients' features

From: Prognostic value of KRAS genotype in metastatic colorectal cancer (MCRC) patients treated with intensive triplet chemotherapy plus bevacizumab (FIr-B/FOx) according to extension of metastatic disease

  KRASwild-type, no. (%) KRASmutant, no. (%) Total no. (%)
No. of patients 31 (53) 28 (47) 59
Male/female 21/10 16/12 37/22
Age, years:    
Median 64 65 63
Range 42 to 73 48 to 73 42 to 73
≥65 13 (42) 13 (46) 26 (44)
WHO performance status:    
0 28 (90) 26 (93) 54 (92)
1 to 2 3 (10) 2 (7) 5 (8)
Metastatic disease:    
Metachronous 10 (32) 7 (25) 17 (29)
Synchronous 21 (68) 21 (75) 42 (71)
Primary tumor:    
Colon 14 (45) 20 (71) 34 (58)
Rectum 17 (55) 8 (29) 25 (42)
Sites of metastases:    
Liver 19 (61) 20 (71) 39 (66)
Lung 7 (23) 5 (18) 12 (20)
Lymph nodes 10 (32) 8 (29) 18 (30)
Local 6 (19) 3 (11) 9 (15)
Other 2 (6) 6 (21) 8 (14)
No. of involved sites:    
1 17 (55) 17 (61) 34 (58)
≥2 14 (45) 11 (39) 25 (42)
Single metastatic sites:    
Liver limited 12 (39) 13 (46) 25 (42)
Other than liver 7 (22) 4 (15) 11 (19)
   Lung    2 (6)    2 (7)    4 (7)
   Lymph nodes    2 (6)    1 (4)    3 (5)
   Local    3 (10)    1 (4)    4 (7)
Multiple metastatic sites 12 (39) 11 (39) 23 (39)
Liver metastases:    
Single 8 (26) 3 (11) 11 (19)
Multiple 11 (35) 11 (39) 22 (37)
Previous adjuvant chemotherapy: 6 (19) 2 (7) 8 (14)
FA/5-FU bolus 3 (10) - 3 (5)
Capecitabine - - -
FOLFOX4 2 (6) 2 (7) 4 (7)
XelOx 1 (3) - 1 (2)
Previous radiotherapy: 4 (13) 1 (4) 5 (8)
Radiotherapy alone - - -
Radiotherapy + chemotherapy (5-FU continuous infusion) 2 (6) - 2 (3)
Radiotherapy + chemotherapy (XELOX) 2 (6) 1 (4) 3 (5)
  1. WHO = World Health Organization.